Saniona AB

Headquarters: Glostrup, Denmark

Employees: 53

CEO: Mr. Rami Levin

show_chart FSX: 30S +5.01%

Market Cap

€18.2 Million

EUR as of Jan. 1, 2023

US$19.4 Million

history Market Cap History

Saniona AB market capitalization over time

Evolution of Saniona AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Saniona AB

Detailed Description

Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. The company's products include Tesofensine, a triple monoamine reuptake inhibitor; Tesomet, a fix-dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; and CAD-1883 for movement disorders. It is also developing SAN711 for rare neuropathic disorders, which is in Phase 1; SAN903 that is in preclinical stage for rare inflammatory/fibrotic disorders; and Boehringer Ingelheim program for schizophrenia. In addition, it has a portfolio of various drug candidates in pre-clinical and clinical stages. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Stocks & Indices

Saniona AB has the following listings and related stock indices.

Stock: FSX: 30S




Smedeland 26B

Glostrup, 2600


Phone: 45 70 70 52 25